Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053116 · ClinicalTrials.gov registry record · Phase 2
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02053116 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT02053116, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG PF-05175157
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02053116
The ClinicalTrials.gov registry entry for NCT02053116 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02053116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02053116 about?
NCT02053116 is a clinical study titled "A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin". A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).
What is the current status of trial NCT02053116?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-03. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02053116?
The interventions under investigation include: Placebo (DRUG), PF-05175157 (DRUG).
Who is sponsoring clinical trial NCT02053116?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.